⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29169854 | 1.00 | — | — | |
| SCHEMBL30763427 | 0.83 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL28572308 | 0.73 | — | — | |
| SCHEMBL29114046 | 0.65 | — | — | |
| SCHEMBL4911627 | 0.64 | — | — | |
| SCHEMBL9651765 | 0.64 | — | — | |
| SCHEMBL28623899 | 0.64 | — | — | |
| SCHEMBL28773049 | 0.63 | TET2 (0.32) | — | |
| SCHEMBL4845814 | 0.62 | — | — | |
| SCHEMBL6398682 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559933-A1 | MUTANT PROMOTING HOMOLOGOUS PAIRING OF HEAVY AND LIGHT CHAINS OF MULTISPECIFIC ANTIBODY | Innovent Biologics (Suzhou) Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017371-A9 | MUTANT PROMOTING HOMOLOGOUS PAIRING OF HEAVY AND LIGHT CHAINS OF MULTISPECIFIC ANTIBODY | 信达生物制药(苏州)有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119604525-A | Mutants promoting homologous pairing of heavy and light chains of multispecific antibodies | 信达生物制药(苏州)有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | SEAGEN INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | JPMORGAN CHASE BANK, N.A. | 2024-07-25 | — | — | US | disclosed |
| EP-3900742-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4346906-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | Seagen Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117580593-A | Anthracycline antibody conjugates | 思进公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024017371-A1 | MUTANT PROMOTING HOMOLOGOUS PAIRING OF HEAVY AND LIGHT CHAINS OF MULTISPECIFIC ANTIBODY | 信达生物制药(苏州)有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-114732916-B | Targeted delivery of tertiary amine-containing drug substances | 西雅图基因公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2006078821-A2 | PRODUCTS AND PROCESSES FOR IN VITRO SYNTHESIS OF BIOMOLECULES | INVITROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060141529-A1 | Compositions, kits and assays containing reagents directed to cortactin and an ARG/ABL protein kinase | Life Technologies Corporation | 2006-06-29 | — | — | US | disclosed |
| US-20060100788-A1 | Collections of matched biological reagents and methods for identifying matched reagents | INVITROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2006015084-A2 | COMPOSITIONS, KITS AND ASSAYS CONTAINING REAGENTS DIRECTED TO CORTACTIN AND AN ARG/ABL PROTEIN KINASE | INVITROGEN CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050282755-A1 | Compositions having antimicrobial activity and uses thereof | ANSATA THERAPEUTICS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005113812-A2 | COLLECTIONS OF MATCHED BIOLOGICAL REAGENTS AND METHODS FOR IDENTIFYING MATCHED REAGENTS | INVITROGEN CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050233341-A1 | Methods for identifying risk of melanoma and treatments thereof | SEQUENOM, INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005090385-A2 | COMPOSITIONS HAVING ANTIMICROBIAL ACTIVITY AND USES THEREOF | ANSATA THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005051976-A2 | PROTEIN AND PEPTIDE LIGATION PROCESSES AND ONE-STEP PURIFICATION PROCESSES | ANSATA THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005017176-A2 | METHODS FOR IDENTIFYING RISK OF MELANOMA AND TREATMENTS THEREOF | SEQUENOM, INC. (US) | 2005-02-24 | — | — | WO | disclosed |